Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will report first quarter 2026 financial results on May 13, 2026 before the market open and will host a conference call and webcast at 8:30am ET.
Investor dial-in numbers, conference ID 13760062, and a webcast replay will be available on Milestone's website.
Positive
- None.
Negative
- None.
News Market Reaction – MIST
In the May 6 session, MIST gained 4.79%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings date notice | Neutral | +2.3% | Set timing for Q4 and full-year 2025 results with investor call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news drew a modest positive reaction, suggesting investors sometimes position ahead of results.
Over recent months, Milestone has transitioned into commercial stage with CARDAMYST, gaining FDA approval and initial formulary access while reporting a larger net loss and modest 2025 revenue. The company also set prior earnings announcement timing on March 20, 2026, which saw a 2.34% move. Today’s first‑quarter 2026 earnings date notice continues this pattern of pre‑announcing results and investor calls as commercialization progresses.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter ended March 31, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.
Conference Details:
| Conference Date: | Wednesday, May 13, 2026 |
| Conference Time: | 8:30am ET |
| Conference Dial-in: | 1-877-407-0792 |
| International Dial-in: | 1-201-689-8263 |
| Conference ID: | 13760062 |
| Webcast link: | Click here. |
Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to scheduled start time.
A replay of the audio webcast of the call will be available under the News & Events section of Milestone's website, www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
